# A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects

> **NCT00392925** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 177 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** pramlintide acetate 360 mcg
- **DRUG:** metreleptin
- **DRUG:** placebo-pramlintide 600 uL
- **DRUG:** placebo-metreleptin 1 mL
- **DRUG:** Pramlintide acetate 180 mcg

## Key facts

- **NCT ID:** NCT00392925
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2015-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392925, "A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT00392925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*